ПРОДУКТЫ МЕТАБОЛИЗМА КИШЕЧНОЙ МИКРОФЛОРЫ: ВОЗМОЖНА ЛИ ИЗБИРАТЕЛЬНАЯ КОРРЕКЦИЯ?
https://doi.org/10.15690/vsp.v14i2.1289
Аннотация
Об авторах
А. И. Хавкин
Российский научно-исследовательский медицинский университет им. Н.И. Пирогова, Москва, Российская Федерация
Россия
Россия
доктор медицинских наук, профессор, заведующий отделом гастроэнтерологии НИКИ педиатрии РНИМУ им. Н.И. Пирогова
Адрес: 125412, Москва, ул. Талдомская, д. 2, тел.: +7 (499) 487-46-81
О. Н. Комарова
Российский научно-исследовательский медицинский университет им. Н.И. Пирогова, Москва, Российская Федерация
Россия
Россия
Список литературы
1. Moore W. E., Holdeman L. V. Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl. Microbiol. 1974; 27: 961–979.
2. Noack J., Kleessen B., Proll J., Dongowski G., Blaut M. Dietary guar gum and pectin stimulate intestinal microbial polyamine synthesis in rats. J. Nutr. 1998; 128: 1385–1391.
3. Khavkin A.I. Mikroflora pishchevaritel'nogo trakta [Microflora of the Digestive System]. Moscow, Fond sotsial'noi pediatrii, 2006. 416 p.
4. Ursova N.I. Disbakteriozy kishechnika v detskom vozraste: innovatsii v diagnostike, korrektsii i profilaktike [Intestinal Dysbiosis in Children: Innovations in the Diagnosis, Prevention and Correction]. Moscow, 2013. 328 p.
5. Limanova O.A., Fedotova L.E., Sadin A.V. Klinicheskaya farmakologiya preparatov, primenyaemykh dlya lecheniya disbakterioza kishechnika [Clinical Pharmacology of Drugs used for Treatment of Intestinal Dysbiosis]. Ivanovo, 2007. 23 p.
6. Kilkkinen A., Pietinen P., Klaukka T., Virtamo J., Korhonen P., Adlercreutz H. Use of oral antimicrobials decreases serum enterolactone concentration. Am. J. Epidemiol. 2002; 155: 472–477.
7. Hurley B. W., Nguyen C. C. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch. Intern. Med. 2002; 162: 2177–2184.
8. Macfarlane G. T., Gibson G. R. Metabolic activities of the normal colonic flora. In: Human Health: The Contribution of Microorganisms. S. A. W. Gibson (ed.). London: Springer-Verlag. 1994. P. 17–53.
9. Macfarlane S., Macfarlane G. T. Proteolysis and amino acid fermentation. In: Human Colonic Bacteria: Role in Nutrition, Physiology, and Pathology. G. R. Gibson, G. T. Macfarlane (eds.). Boca Raton, FL: CRC Press. 1995. P. 75–100.
10. Kruis W., Forstmaier G., Scheurlen C., Stellaard F. Effect of diets low and high in refined sugars on gut transit, bile acid metabolism, and bacterial fermentation. Gut. 1991; 32: 367–371.
11. WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria (October 2001). «Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria». Food and Agriculture Organization of the United Nations, World Health Organization. http://www.who.int/ foodsafety/publications/fs_management/en/probiotics.pdf (available: 07.03.2015).
12. Metchnikov I. Essais optimistes. Paris. 1907. 438 p.
13. Roberfroid M. Prebiotics: the concept revisited. J. Nutr. 2007; 137 (Suppl. 3): 830–837.
14. Tabolin V.A., Bel'mer S.V., Gasilina T.V., Mukhina Yu.G., Korneva T.I. Ratsional'naya terapiya disbakterioza kishechnika u detei. Metod. rekomendats [Rational Treatment of Intestinal Dysbiosis in Children. Method. recommendations]. Moscow, 1998. 24 p.
15. Biville F., Laurent-Winter C., Danchin A. In vivo positive effects of exogenous pyrophosphate on Escherichia coli cell growth and stationary phase survival. Res. Microbiol. 1996; 147 (8): 597–608.
16. Gritsenko V. A., Brudastov Iu. A., Kudria E. V., Vasil'eva L. I. Comparative analysis of the sensitivity of enterobacteria to bile. Zh. Mikrobiol. Epidemiol. Immunobiol. 2002; 3: 65–67.
17. Kyriakidis D. A., Tiligada E. Signal transduction and adaptive regulation through bacterial two-component systems: the Escherichia coli AtoSC paradigm. Amino Acids. 2009; 37 (3): 443.
18. Hori Y., Nihei Y., Kurokawa Y., Kuramasu A., Makabe-Kobayashi Y., Terui T., Doi H., Satomi S., Sakurai E., Nagy A., Wata nabe T., Ohtsu H. Accelerated clearance of Escherichia coli in experi mental peritonitis of histamine-deficient mice. J. Immunol. 2002; 169 (4): 1978–1983.
19. Bailey M. T., Coe C. L. Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys. Dev. Psychobiol. 1999; 35: 146–155.
20. Lyte M., Ernst S. Catecholamine induced growth of gram negative bacteria. Life Sci. 1992; 50: 203–212.
21. Hall-Stoodley L., Costerton J. W., Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2004; 2 (2): 95–108.
22. Bukharin O. V., Petrunova N. B. Microbial «friend-foe» identifi-ca tion in human intestine microsymbiocenosis. Zh. Mikrobiol. Epidemiol. Immunobiol. 2011; 6: 46–51.
23. Yates E. A., Philipp B., Buckley C., Atkinson S., Chhabra S. R., Sockett R. E., Goldner M., Dessaux Y., Camara M., Smith H., Williams P. N-acylhomoserine lactones undergo lactonolysis in a pH-, temperature-, and acyl chain length-dependent manner during growth of Yersinia pseudotuberculosis and Pseudomonas aeruginosa. Infect. Immun. 2002; 70 (10): 5635–5646.
24. Wang X. D., de Boer P. A., Rothfield L. I. A factor that positively regulates cell division by activating transcription of the major cluster of essential cell division genes of Escherichia coli. EMBO J. 1991; 10 (11): 3363–3372.
25. Qazi S., Middleton B., Muharram S. H., Cockayne A., Hill P., O'Shea P., Chhabra S. R., Camara M., Williams P. N-acylhomoserine lactones antagonize virulence gene expression and quorum sensing in Staphylococcus aureus. Infect. Immun. 2006; 74 (2): 910–919.
26. Hall R. A., Turner K. J., Chaloupka J., Cottier F., De Sordi L., Sanglard D., Levin L. R., Buck J., Muhlschlegel F. A. The quorum-sensing molecules farnesol/homoserine lactone and dodecanol operate via distinct modes of action in Candida albicans. Eukaryot. Cell. 2011; 10 (8): 1034–1042.
27. Miller M. B., Bassler B. L. Quorum sensing in bacteria. Ann. Rev. Microbiol. 2001; 55: 165–199.
28. Diggle S. P., Gardner A., West S. A., Griffin A. S. Evolutionary theory of bacterial quorum sensing: when is a signal not a signal? Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2007; 362 (1483): 1241–1249.
29. Lyte M., Frank C. D., Green B. T. Production of an autoinducer of growth by norepinephrine cultured Escherichia coli 0157: H7. FEMS Microbiol. Lett. 1996; 139: 155–159.
30. Shimazaki J., Furukawa S., Ogihara H., Morinaga Y. L-Tryptophan pre vents Escherichia coli biofilm formation and triggers biofilm degra dation. Biochem. Biophys. Res. Commun. 2012; 419 (4): 715–718.
31. Vacheva A., Ivanova R., Paunova-Krasteva T., Stoitsova S. Released products of pathogenic bacteria stimulate biofilm formation by Escherichia coli K-12 strains. Antonie Van Leeuwenhoek. 2012; 102 (1): 105–119.
32. Kumari A., Pasini P., Deo S. K., Flomenhoft D., Shashidhar H., Daunert S. Biosensing systems for the detection of bacterial quorum signaling molecules. Anal. Chem. 2006; 78 (22): 7603–7609.
33. Vakhitov T.Ya., Protasov E. A., Visnol'd N. V., Tolparov Yu. T., Petrov L. N. Isolation and identification of growth stimulators of Escherichia coli M-17. Zh. Mikrobiol. Epidemiol. Immunobiol. 2003; 2: 7–12.
34. Gromova O.A., Torshin I.Yu., Grishina T.R., Garas'ko E.V. Molecular Mechanisms of metabolic effects of prebiotic Hilak Fort intestinal biofloru and exchange of vitamins. Russian Union Medical Professions. Zhurnal Gastro = Russian Union Medical Professions. Gastro Journal. 2013;1:11–16.
35. Torshin I.Yu., Gromova O.A. 25 mgnovenii molekulyarnoi farmakologii [25 Moments of Molecular Pharmacology]. Moscow, A-Grif, 2012. 678 p.
36. Joshi-Tope G., Gillespie M., Vastrik I., D'Eustachio P., Schmidt E., de Bono B., Jassal B., Gopinath G. R., Wu G., Matthews L., Lewis S., Birney E., Stein L. Reactome: a knowledgebase of biological pathways. Nucleic Acids Res. 2005; 33: 428–432.
37. Gromova O.A., Torshin I.Yu., Volkov A.Yu., Lisitsa A.V., Garas'ko E.V. Molecular mechanisms of the metabolic effects of prebiotics on the survival of the positive microflora. Lechashchii vrach = Practicing doctor. 2013;6:79–83.
38. Bentley R., Meganathan R. Biosynthesis of vitamin K (menaquinone) in bacteria. Microbiol. Rev. 1982; 46 (3): 241–280.
39. Reid G., Howard J., Gan B. S. Can bacterial interference prevent infection? Trends Microbiol. 2001; 9 (9): 424–428.
40. Aihara K., Kajimoto O., Hirata H., Takahashi R., Nakamura Y. Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J. Am. Coll. Nutr. 2005; 24 (4): 257–265.
41. Schlegel A., Bohm A., Lee S. J., Peist R., Decker K., Boos W. Network regulation of the Escherichia coli maltose system. J. Mol. Microbiol. Biotechnol. 2002; 4 (3): 301–307.
42. Bochner B. R., Gadzinski P., Panomitros E. Phenotype micro-arrays for high-throughput phenotypic testing and assay of gene function. Genome Res. 2001; 11 (7): 1246–1255.
43. Khavkin A.I. Mikroflora pishchevaritel'nogo takta [Microflora of the Digestive System]. Moscow, FSP, 2012. 424 p.
44. Florkiewicz H., Szurska G. Role of the Hylak forte preparation in the prevention of dysbacteriosis following intraoral antibiotic therapy. Pol. Tyg. Lek. 1963;18:1066–1068.
45. Agafonova N.A., Yakovenko E.P., Ivanov A.N., Yakovenko A.V., Pryanishnikova A.S. Features of treatment of patients with post-infectious irritable bowel syndrome. Farmateka = Pharmateca. 2011;15:50–55.
46. Burkov S.G., Makukh E.A. Irritable bowel syndrome in outpatient practice. Farmateka = Pharmateca. 2009;8:60–64.
47. Ardatskaya M.D. Pre- and probiotics correction microecological bowel disorders. Farmateka = Pharmateca. 2011;12:62–68.
48. Khavkin A.I. Microflora and development of the immune system. Detskaya gastroenterologiya = Pediatric gastroenterology. 2010;4(3):34–37.
49. Ploskireva A.A., Usenko D.V., Gorelov A.V. Adaptogenic properties metabolite prebiotic Hilak forte. Infektsionnye bolezni = Infectious diseases. 2010;8(1):48–54.
50. Gracheva N.M., Malyshev N.A., Leont'eva N.I., Kondrakova O.A., Partin O.S., Solov'eva A.I., Zatevalov A.M., Koshkina N.K. Restoring metabolite status of intestinal microflora in patients with chronic diseases of the gastrointestinal tract. Infektsionnye bolezni = Infectious diseases. 2006;4(2):37–41.
51. Rudkowski Z., Bromirska J. Reduction of the duration of salmonella excretion in infants with Hylak forte. Padiatr. Padol. 1991; 26 (2): 111–114.
52. Gracheva N.M., Partin O.S., Leont'eva N.I., Shcherbakov I.T., Solov'eva A.I. Application of modern prebiotic Hilak forte in the treatment of patients with acute intestinal infections and chronic diseases of the gastrointestinal tract with symptoms of intestinal dysbiosis Epidemiologiya i infektsionnye bolezni = Epidemiology and infectious diseases. 2003;5:32.
Рецензия
Для цитирования:
Хавкин А.И., Комарова О.Н. ПРОДУКТЫ МЕТАБОЛИЗМА КИШЕЧНОЙ МИКРОФЛОРЫ: ВОЗМОЖНА ЛИ ИЗБИРАТЕЛЬНАЯ КОРРЕКЦИЯ? Вопросы современной педиатрии. 2015;14(2):212-218. https://doi.org/10.15690/vsp.v14i2.1289
For citation:
Khavkin A.I., Komarova O.N. PRODUCTS OF METABOLISM OF THE INTESTINAL MICROFLORA: CAN WE USE THE SELECTIVE CORRECTION? Current Pediatrics. 2015;14(2):212-218. (In Russ.) https://doi.org/10.15690/vsp.v14i2.1289
Просмотров: 1261
Послать статью по эл. почте 
